Liproxstatin-1
目录号:S7699 Purity: 99.78%
Liproxstatin-1是一种有效的ferroptosis抑制剂,IC50为22 nM。
CAS: 950455-15-9
客户使用Selleck的Liproxstatin-1发表文献229篇
- Nature, 2024 626(7998):411-418.
- Mol Cancer, 2024 23(1):113
- Cell Metab, 2024 S1550-4131(24)00371-1
- Nat Cell Biol, 2024 10.1038/s41556-024-01450-7
- Nature, 2023 619(7969):371-377
- Cell Res, 2023 10.1038/s41422-023-00848-6
- Signal Transduct Target Ther, 2023 8(1):103
- Cell Discov, 2023 9(1):104
- Cell Metab, 2023 35(7):1147-1162.e7
- J Hematol Oncol, 2023 16(1):30
- Nature, 2022 10.1038/s41586-022-05022-3
- Science, 2022 375(6586):1254-1261
- Signal Transduct Target Ther, 2022 7(1):59
- Nat Immunol, 2021 10.1038/s41590-021-01090-1
- Nat Immunol, 2021 22(9):1107-1117
- Cell Metab, 2021 S1550-4131(21)00233-3
- Signal Transduct Target Ther, 2020 8;5(1):51
- Nat Immunol, 2020 21(7):727-735
- Nat Cell Biol, 2020 22(9):1042-1048
- Nat Nanotechnol, 2016 11(11):977-985
- Nat Struct Mol Biol, 2024 10.1038/s41594-024-01329-z
- Nat Commun, 2024 15(1):9550
- Nat Commun, 2024 15(1):7522
- Nat Commun, 2024 15(1):3816
- Nat Commun, 2024 15(1):1429
- Adv Sci (Weinh), 2024 11(20):e2305934
- J Exp Clin Cancer Res, 2024 43(1):112
- J Immunother Cancer, 2024 12(11)e009805
- J Nanobiotechnology, 2024 22(1):479
- MedComm (2020), 2024 5(8):e684
- Cancer Lett, 2024 592:216898
- Cell Death Dis, 2024 15(11):819
- Cell Death Dis, 2024 15(9):695
- Cell Death Dis, 2024 15(3):178
- J Transl Med, 2024 22(1):9
- Front Immunol, 2024 15:1490845
- Antioxidants (Basel), 2024 13(2)182
- Cell Death Discov, 2024 10(1):108
- Antioxidants (Basel), 2024 13(1)114
- Oncogenesis, 2024 13(1):31
- Front Pharmacol, 2024 15:1480345
- Biol Direct, 2024 19(1):81
- Virol Sin, 2024 39(1):144-155
- J Virol, 2024 98(3):e0189723
- J Cell Mol Med, 2024 28(1):e17983
- Hepatol Commun, 2024 8(3)e0396
- Chin Med, 2024 19(1):52
- J Biol Chem, 2024 300(12):107942
- Sci Rep, 2024 14(1):6655
- Acta Biochim Biophys Sin (Shanghai), 2024 56(10):1537-1548
- Exp Cell Res, 2024 438(1):114029
- J Cancer Res Clin Oncol, 2024 150(5):228
- Autoimmunity, 2024 57(1):2410192
- Brain Res, 2024 1838:149011
- Mol Biotechnol, 2024 10.1007/s12033-024-01084-y
- Sci Adv, 2024 10(7):eadk1835
- bioRxiv, 2024 2024.07.25.605098
- Cell Rep Methods, 2024 S2667-2375(24)00025-0
- Nat Struct Mol Biol, 2023 10.1038/s41594-023-01136-y
- Nat Commun, 2023 14(1):7916
- Nat Commun, 2023 14(1):4403
- Adv Sci (Weinh), 2023 10(6):e2204006
- Nat Commun, 2023 14(1):5456
- Cell Death Differ, 2023 30(8):1988-2004
- Redox Biology, 2023 Volume 62
- Redox Biol, 2023 62:102708
- Redox Biol, 2023 62:102678
- Cancer Res, 2023 83(2):251-263
- Cell Death Dis, 2023 14(8):532
- Cell Death Dis, 2023 14(1):48
- Br J Cancer, 2023 129(4):601-611
- Cell Rep, 2023 42(9):113110
- Elife, 2023 12RP88745
- Free Radic Biol Med, 2023 202:110-120
- Oxid Med Cell Longev, 2023 2023:9808100
- Cell Death Discov, 2023 9(1):428
- Antioxidants (Basel), 2023 12(12)2119
- Antioxid Redox Signal, 2023 39(1-3):166-185.
- Chin Med J -Engl), 2023 136(18):2210-2220
- Neural Regen Res, 2023 18(11):2474-2481
- Commun Biol, 2023 6(1):1108
- Mol Med, 2023 29(1):42
- Front Pharmacol, 2023 14:1145407
- J Cell Mol Med, 2023 10.1111/jcmm.17855
- Cancers (Basel), 2023 15(24)5866
- Cancers (Basel), 2023 15(6)1880
- Chem Biol Interact, 2023 384:110712
- Transl Oncol, 2023 10.1016/j.tranon.2023.101817
- Ann Transl Med, 2023 11(1):3
- Sci Rep, 2023 13(1):16893
- Transl Lung Cancer Res, 2023 12(8):1766-1781
- Pulm Pharmacol Ther, 2023 84:102284
- Toxicol In Vitro, 2023 92:105655
- Evid Based Complement Alternat Med, 2023 2023:8378581
- Open Life Sci, 2023 18(1):20220678
- Transl Cancer Res, 2023 12(9):2294-2307
- Mol Cell, 2022 82(5):920-932.e7
- Adv Sci (Weinh), 2022 9(28):e2203357
- Adv Sci (Weinh), 2022 10.1002/advs.202204697
- Cell Death Differ, 2022 10.1038/s41418-022-01050-8
- Cell Death Differ, 2022 10.1038/s41418-022-01008-w
- Cell Death Differ, 2022 10.1038/s41418-022-00957-6
- Redox Biol, 2022 57:102518
- Redox Biol, 2022 56:102451
- Redox Biol, 2022 57:102509
- Redox Biol, 2022 52:102292
- J Neuroinflammation, 2022 19(1):185
- Pharmacol Res, 2022 182:106306
- Int J Biol Sci, 2022 18(10):4118-4134
- Cell Death Dis, 2022 13(11):1000
- Cell Death Dis, 2022 13(6):521
- Cell Death Dis, 2022 13(2):150
- Cell Rep, 2022 41(6):111610
- Cell Mol Life Sci, 2022 79(5):228
- Cell Biosci, 2022 12(1):42
- Biomed Pharmacother, 2022 148:112742
- Free Radic Biol Med, 2022 194:84-98
- Oxid Med Cell Longev, 2022 2022:1366957
- Oxid Med Cell Longev, 2022 2022:3403009
- Cell Death Discov, 2022 8(1):414
- Cells, 2022 11(22)3580
- iScience, 2022 25(11):105406
- Front Cell Dev Biol, 2022 10:806081
- Cancers (Basel), 2022 14(14)3410
- Int J Oncol, 2022 61(4)119
- Cancers (Basel), 2022 14(19)4690
- Cancers (Basel), 2022 14(20)5050
- Chem Biol Interact, 2022 369:110262
- Eur J Pharmacol, 2022 924:174970
- Bioengineered, 2022 13(2):4063-4075
- FASEB J, 2022 36(12):e22649
- Front Oncol, 2022 12:1025067
- J Cancer, 2022 13(11):3234-3243
- Pharm Biol, 2022 60(1):1449-1457
- Metallomics, 2022 14(5)mfac027
- Mol Cell Probes, 2022 S0890-8508(22)00032-9
- Free Radic Res, 2022 1-11
- Anal Cell Pathol (Amst), 2022 2022:2843990
- Anal Cell Pathol (Amst), 2022 2022:4213401
- Biochem Biophys Res Commun, 2022 606:68-74
- Biochem Biophys Res Commun, 2022 595:7-13
- Prostate, 2022 10.1002/pros.24308
- Neoplasma, 2022 69(3):648-656
- Curr Protoc, 2022 2(4):e413
- Nat Commun, 2021 12(1):6399
- Nat Commun, 2021 12(1):647
- J Clin Invest, 2021 e152067
- Autophagy, 2021 10.1080/15548627.2021.2008692
- Autophagy, 2021 1-14
- Cell Death Differ, 2021 10.1038/s41418-020-00685-9
- Redox Biol, 2021 47:102151
- Clin Transl Med, 2021 11(4):e390
- Cell Death Dis, 2021 12(9):834
- Cell Death Dis, 2021 12(7):698
- Cell Rep, 2021 34(8):108767
- Cell Mol Biol Lett, 2021 26(1):26
- Acta Pharmacol Sin, 2021 10.1038/s41401-021-00700-w
- Elife, 2021 10e68603
- Elife, 2021 10e64806
- Free Radic Biol Med, 2021 163:234-242
- Cell Death Discov, 2021 7(1):374
- Biochim Biophys Acta Mol Basis Dis, 2021 S0925-4439(21)00220-9
- Neural Regen Res, 2021 16(3):561-566
- Biochem Pharmacol, 2021 193:114813
- iScience, 2021 24(8):102837
- Front Pharmacol, 2021 12:670224
- Neurosci Bull, 2021 10.1007/s12264-020-00620-5
- Biomolecules, 2021 12(1)48
- Am J Cancer Res, 2021 11(3):691-711
- J Mol Cell Cardiol, 2021 150:65-76
- Dig Liver Dis, 2021 S1590-8658(21)00063-3
- Gene, 2021 S0378-1119(21)00587-4
- Free Radic Res, 2021 1-22
- Free Radic Res, 2021 1-18
- Biochem Biophys Res Commun, 2021 576:33-39
- Biochem Biophys Res Commun, 2021 536:100-106
- Sci Adv, 2021 7(47):eabk1023
- bioRxiv, 2021 10.1101/2021.04.07.438684
- STAR Protoc, 2021 2(1):100360
- Nat Commun, 2020 11(1):6339
- Nat Commun, 2020 23;11(1):433
- Mol Cell, 2020 S1097-2765(20)30802-9
- Autophagy, 2020 18;1-13
- Theranostics, 2020 6;10(11):5107-5119
- Cancer Res, 2020 canres.530.2020
- Proc Natl Acad Sci U S A, 2020 117(44):27319-27328
- Br J Cancer, 2020 122(2):279-292
- Acta Pharmacol Sin, 2020 10.1038/s41401-020-0376-8
- Oxid Med Cell Longev, 2020 2020:1782659
- Oxid Med Cell Longev, 2020 4;2020:5021983
- Int J Cancer, 2020 147(11):3224-3235
- Cancer Gene Ther, 2020 10.1038/s41417-020-0182-y
- J Cell Physiol, 2020 24
- CNS Neurosci Ther, 2020 10.1111/cns.13548
- J Cell Mol Med, 2020 10.1111/jcmm.15839
- FASEB J, 2020 10.1096/fj.202001758R
- Biochem Biophys Res Commun, 2020 523(4):966-971
- Dig Dis Sci, 2020 27
- Biochem Biophys Res Commun, 2020 525(3):620-625
- Anticancer Drugs, 2020 31(1):27-34
- Sci Adv, 2020 25;6(13):eaay9789
- ACS Nano, 2019 13(1):260-273
- Cell Death Differ, 2019 10.1038/s41418-019-0299-4
- J Exp Clin Cancer Res, 2019 38(1):461
- Front Pharmacol, 2019 10:638
- PLoS One, 2019 14(12):e0227278
- Cancer Manag Res, 2019
- Biochem Biophys Res Commun, 2019 10.1016/j.bbrc.2019.11.110
- Biochem Biophys Res Commun, 2019 510(2):278-283
- Autophagy, 2018 14(12):2083-2103
- Curr Biol, 2018 28(15):2388-2399
- Cell Death Dis, 2018 9(7):753
- Oncoimmunology, 2018 7(6):e1431086
- Arch Toxicol, 2018 92(4):1507-1524
- Front Pharmacol, 2018 9:1371
- Int J Mol Med, 2018 41(5):3051-3062
- Int J Oncol, 2018 52(3):1011-1022
- Biochem Biophys Res Commun, 2018 503(3):1550-1556
- Pathol Oncol Res, 2018 10.1007/s12253-018-0539-9
- Redox Biol, 2017 12:8-17
- Cancer Res, 2017 77(8):2064-2077
- Mol Psychiatry, 2017 22(11):1520-1530
- Cell Rep, 2017 20(7):1692-1704
- Neoplasia, 2017 19(12):1022-1032
- Hepatology, 2016 64(2):488-500
- Hepatology, 2016 63(1):173-84
- Oncol Rep, 2016 36(2):968-76
- Biochem Biophys Res Commun, 2016 480(3):443-449
- Biochem Biophys Res Commun, 2016 473(4):775-80
化学信息&溶解度
分子量 | 340.85 |
分子式 | C19H21ClN4 |
CAS号 | 950455-15-9 |
Smiles | C1CNCCC12C(=NCC3=CC(=CC=C3)Cl)NC4=CC=CC=C4N2 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 68 mg/mL ( 199.5 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 34 mg/mL Water : Insoluble DMSO : 68 mg/mL ( 199.5 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 5 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
2%DMSO
40%PEG300
2%Tween80
56%ddH2O
浓度:3mg/ml
(8.80mM)
操作示例:以 1 mL 工作液为例,取20μL150mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入20μLTween80,混合均匀使其澄清;然后继续加入560μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。